儿科失神癫痫治疗市场：依药物（拉莫三嗪、丙戊酸）、依疾病类型（非典型失神发作、典型失神发作）-2023-2030 年全球预测

预计2023年全球儿科失神癫痫药物市场将达2.3776亿美元，复合年增长率为7.41%，大幅成长，2030年将达到3.9281亿美元。

FPNV定位矩阵

FPNV定位矩阵对于评估全球儿科失神癫痫药物市场至关重要。透过检查业务策略和产品满意度的关键指标，我们对供应商进行全面评估，使您能够根据您的特定需求做出明智的资讯。这种进阶分析将供应商分为四个像限，并取得了不同程度的成功：前沿 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市占率分析

市场占有率分析可以深入了解供应商在特定市场领域的当前地位。比较供应商对总收入、基本客群和其他关键指标的贡献，可以帮助公司更好地了解他们在争夺市场份额时的表现以及面临的情况。该分析还揭示了特定行业的竞争程度、累积和合併的优势以及研究基准年的合併特征。

本报告提供了以下几点见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开发：提供有关利润丰厚的新兴市场的详细资讯，并分析其在成熟市场的渗透率。

3. 市场多元化：提供有关新产品发布、未开发地区、最新发展和投资的详细资讯。

4.市场趋势：全面了解COVID-19、俄罗斯-乌克兰衝突和高通膨的累积影响。

5.竞争评估与资讯：对主要企业的市场占有率、策略、产品、认证、法规状况、专利状况、製造能力等进行综合评估。

6. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告回答了以下问题：

1.小儿失神性癫痫治疗药物全球市场规模及预测为何？

2.在预测期内，COVID-19 影响全球小儿失神癫痫药物市场的阻碍因素与影响有哪些？

3.在预测期内，全球小儿失神癫痫药物市场需要投资哪些产品/细分市场/应用/领域？

4.全球儿童失神癫痫药物市场的竞争策略为何？

5. 全球儿科失神性癫痫药物市场的技术趋势和法律规范是什么？

6.全球儿科失神癫痫药物市场主要厂商的市占率为何？

7. 哪些型态和策略性倡议被认为适合进入儿科失神癫痫药物全球市场？

目录

第1章前言

第2章调查方法

第3章执行摘要

第4章市场概况

第5章市场洞察

• 市场动态
  • 促进因素
    • 儿童癫痫和惊厥盛行率上升
    • 政府对儿童失神癫痫的援助
    • 提高家长CAE意识
  • 抑制因素
    • 与药物副作用相关的风险
  • 机会
    • 开发新药的持续研究和开发活动
    • 失神癫痫发作的新治疗方法出现
  • 任务
    • 缺乏有效且可耐受的初始经验性治疗
• 市场趋势
• COVID-19 的累积影响
• 俄罗斯-乌克兰衝突的累积影响
• 高通膨的累积效应
• 波特五力分析
• 价值炼和关键路径分析
• 法律规范
• 客户客製化

第6章儿童失神癫痫治疗药物市场（按药物）

• 拉莫三嗪
• 丙戊酸

第7章小儿失神癫痫药物市场：依疾病类型

• 非典型失神发作
• 典型失神发作

第8章北美与南美小儿失神癫痫药物市场

• 阿根廷
• 巴西
• 加拿大
• 墨西哥
• 美国

第9章亚太地区小儿失神癫痫药物市场

• 澳洲
• 中国
• 印度
• 印尼
• 日本
• 马来西亚
• 菲律宾
• 新加坡
• 韩国
• 台湾
• 泰国
• 越南

第10章欧洲、中东和非洲儿童失神癫痫药物市场

• 丹麦
• 埃及
• 芬兰
• 法国
• 德国
• 以色列
• 义大利
• 荷兰
• 奈及利亚
• 挪威
• 波兰
• 卡达
• 俄罗斯
• 沙乌地阿拉伯
• 南非
• 西班牙
• 瑞典
• 瑞士
• 土耳其
• 阿拉伯聯合大公国
• 英国

第11章竞争形势

• FPNV定位矩阵
• 市占率分析：主要企业
• 竞争情境分析：主要企业

第12章上市公司名单

第13章附录

• 讨论指南
• 关于许可证和定价

The Global Childhood Absence Epilepsy Treatment Market is forecasted to grow significantly, with a projected USD 237.76 million in 2023 at a CAGR of 7.41% and expected to reach a staggering USD 392.81 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Childhood Absence Epilepsy Treatment Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Childhood Absence Epilepsy Treatment Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Drug, market is studied across Lamotrigine and Valproate. The Valproate is projected to witness significant market share during forecast period.

Based on Disease Type, market is studied across Atypical Absence Seizures and Typical Absence Seizures. The Typical Absence Seizures is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.74% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Childhood Absence Epilepsy Treatment Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Childhood Absence Epilepsy Treatment Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Childhood Absence Epilepsy Treatment Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Childhood Absence Epilepsy Treatment Market?

4. What is the competitive strategic window for opportunities in the Global Childhood Absence Epilepsy Treatment Market?

5. What are the technology trends and regulatory frameworks in the Global Childhood Absence Epilepsy Treatment Market?

6. What is the market share of the leading vendors in the Global Childhood Absence Epilepsy Treatment Market?

7. What modes and strategic moves are considered suitable for entering the Global Childhood Absence Epilepsy Treatment Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Limitations
• 1.7. Assumptions
• 1.8. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Childhood Absence Epilepsy Treatment Market, by Drug, 2022 vs 2030
• 4.3. Childhood Absence Epilepsy Treatment Market, by Disease Type, 2022 vs 2030
• 4.4. Childhood Absence Epilepsy Treatment Market, by Region, 2022 vs 2030

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of epilepsy and seizures in children
    • 5.1.1.2. Government assistance for childhood absence epilepsy
    • 5.1.1.3. Increasing parents awareness about CAE
  • 5.1.2. Restraints
    • 5.1.2.1. Risk associated with side effects of medications
  • 5.1.3. Opportunities
    • 5.1.3.1. Ongoing research & development activities for novel drug developments
    • 5.1.3.2. Emerging novel treatments for absence seizures
  • 5.1.4. Challenges
    • 5.1.4.1. Lack of efficacious and tolerable initial empirical treatment
• 5.2. Market Trends
• 5.3. Cumulative Impact of COVID-19
• 5.4. Cumulative Impact of Russia-Ukraine Conflict
• 5.5. Cumulative Impact of High Inflation
• 5.6. Porter's Five Forces Analysis
  • 5.6.1. Threat of New Entrants
  • 5.6.2. Threat of Substitutes
  • 5.6.3. Bargaining Power of Customers
  • 5.6.4. Bargaining Power of Suppliers
  • 5.6.5. Industry Rivalry
• 5.7. Value Chain & Critical Path Analysis
• 5.8. Regulatory Framework
• 5.9. Client Customization

6. Childhood Absence Epilepsy Treatment Market, by Drug

• 6.1. Introduction
• 6.2. Lamotrigine
• 6.3. Valproate

7. Childhood Absence Epilepsy Treatment Market, by Disease Type

• 7.1. Introduction
• 7.2. Atypical Absence Seizures
• 7.3. Typical Absence Seizures

8. Americas Childhood Absence Epilepsy Treatment Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Childhood Absence Epilepsy Treatment Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Childhood Absence Epilepsy Treatment Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. FPNV Positioning Matrix
• 11.2. Market Share Analysis, By Key Player
• 11.3. Competitive Scenario Analysis, By Key Player

12. List of Company Mentioned

13. Appendix

• 13.1. Discussion Guide
• 13.2. License & Pricing

LIST OF FIGURES

• FIGURE 1. CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET RESEARCH PROCESS
• FIGURE 2. CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2022 VS 2030
• FIGURE 3. CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2022 VS 2030 (%)
• FIGURE 5. CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2022 VS 2030 (%)
• FIGURE 6. CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY REGION, 2022 VS 2030 (%)
• FIGURE 7. CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET DYNAMICS
• FIGURE 8. CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 9. CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 11. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 12. ASIA-PACIFIC CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 13. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 14. CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2022
• FIGURE 15. CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

• TABLE 1. CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
• TABLE 3. CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 5. CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY LAMOTRIGINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 6. CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY VALPROATE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 7. CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 8. CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ATYPICAL ABSENCE SEIZURES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TYPICAL ABSENCE SEIZURES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 11. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 12. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 13. ARGENTINA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 14. ARGENTINA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 15. BRAZIL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 16. BRAZIL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 17. CANADA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 18. CANADA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 19. MEXICO CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 20. MEXICO CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 21. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 22. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 23. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 24. ASIA-PACIFIC CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 25. ASIA-PACIFIC CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 26. ASIA-PACIFIC CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 27. AUSTRALIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 28. AUSTRALIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 29. CHINA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 30. CHINA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 31. INDIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 32. INDIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 33. INDONESIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 34. INDONESIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 35. JAPAN CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 36. JAPAN CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 37. MALAYSIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 38. MALAYSIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 39. PHILIPPINES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 40. PHILIPPINES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 41. SINGAPORE CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 42. SINGAPORE CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 43. SOUTH KOREA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 44. SOUTH KOREA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 45. TAIWAN CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 46. TAIWAN CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 47. THAILAND CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 48. THAILAND CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 49. VIETNAM CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 50. VIETNAM CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 51. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 52. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 53. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 54. DENMARK CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 55. DENMARK CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 56. EGYPT CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 57. EGYPT CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 58. FINLAND CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 59. FINLAND CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 60. FRANCE CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 61. FRANCE CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 62. GERMANY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 63. GERMANY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 64. ISRAEL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 65. ISRAEL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 66. ITALY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 67. ITALY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 68. NETHERLANDS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 69. NETHERLANDS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 70. NIGERIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 71. NIGERIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 72. NORWAY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 73. NORWAY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 74. POLAND CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 75. POLAND CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 76. QATAR CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 77. QATAR CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 78. RUSSIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 79. RUSSIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 80. SAUDI ARABIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 81. SAUDI ARABIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 82. SOUTH AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 83. SOUTH AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 84. SPAIN CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 85. SPAIN CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 86. SWEDEN CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 87. SWEDEN CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 88. SWITZERLAND CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 89. SWITZERLAND CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 90. TURKEY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 91. TURKEY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 92. UNITED ARAB EMIRATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 93. UNITED ARAB EMIRATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 94. UNITED KINGDOM CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 95. UNITED KINGDOM CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 96. CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2022
• TABLE 97. CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SHARE, BY KEY PLAYER, 2022
• TABLE 98. CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET LICENSE & PRICING